周五,乐普生物发布公告将CTM012、CTM013全球权益授权给Excalipoint,获得1000万美元首付款+10% Excalipoint的普通股+最高8.475亿元的里程碑+10%上下的特许权使用费。乐普生物在公告中还透露了Excalipoint正在进行A轮融资的消息,且参投方有红杉中国、杏泽资本、弘毅资本等众多风投大咖。照此推断Excalipoint未来IPO的确定性应该较强,乐普生物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.